Arbutus updates LNP litigation; Moderna trial March 2026, Pfizer/BioNTech awaits scheduling

Arbutus Biopharma Corp

Global COVID-19 vaccine sales since launch total ~$145BN between Moderna and Pfizer/BioNTech.
US Moderna jury trial set for March 9, 2026 in Delaware; summary judgment/Daubert rulings expected before trial.
Ex-US Moderna litigation initial hearings expected in 2026 in UPC, Japan, Switzerland, Canada.
Pfizer/BioNTech litigation: Markman ruling in Sep 2025 viewed favorably; awaiting trial scheduling.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.